Company Overview

Affimed N.V. is a clinical-stage immuno-oncology company focused on developing innate immune cell engagers designed to harness the body’s natural killer (NK) cells and T cells to treat cancer. The company operates within the biotechnology and pharmaceutical industries, with a primary focus on hematologic malignancies and selected solid tumors. Affimed’s core technology platform centers on its proprietary ROCK® (Redirected Optimized Cell Killing) platform, which is designed to generate tetravalent bispecific antibody therapeutics that activate immune cells against cancer targets.

The company’s primary value drivers have historically included its lead clinical candidates, strategic collaborations, and intellectual property related to innate immune engagement technologies. Key programs have included AFM13, targeting CD30-positive malignancies, and additional ICE® (Innate Cell Engager) candidates directed toward EGFR and other tumor-associated antigens. Affimed was founded in Germany in 2000 and later established a corporate presence in the Netherlands as Affimed N.V., while maintaining substantial research and operational activities in Europe and the United States. The company evolved from an early-stage antibody engineering business into a clinical-stage oncology developer through internal platform development, licensing, and strategic partnerships.

Business Operations

Affimed’s operations have primarily consisted of research and development activities rather than commercial product sales, as the company has not historically generated recurring revenue from approved therapeutics. Revenue has mainly come from collaboration agreements, licensing arrangements, milestone payments, and research funding associated with partnerships. The company’s business has centered on advancing its ROCK® platform, conducting clinical trials, and developing ICE® molecules that engage NK cells and macrophages for anti-cancer activity.

Operationally, Affimed has maintained activities across both Europe and the United States, including clinical development, manufacturing coordination, and regulatory engagement. The company has collaborated with several industry and academic partners, including Genentech/Roche, Artiva Biotherapeutics, and other cell therapy or oncology-focused organizations. Affimed has also explored combination approaches involving cord blood-derived NK cells and checkpoint inhibitors. Public filings and restructuring disclosures indicate the company experienced significant financial distress leading to insolvency-related proceedings and OTC market trading under the symbol AFMDQ. Certain operational details following restructuring announcements remain subject to ongoing public disclosures, and some information is inconclusive based on available public sources.

Strategic Position & Investments

Affimed’s strategic direction has focused on advancing innate immune system-based therapies as differentiated alternatives or complements to traditional T-cell therapies and monoclonal antibodies. The company has emphasized the potential advantages of NK cell engagement, including off-the-shelf treatment compatibility, combination flexibility, and potentially improved safety profiles compared with some autologous cell therapies. Its investment priorities historically included expanding the ICE® pipeline, developing combination regimens, and validating the ROCK® platform across multiple tumor targets.

Major strategic collaborations have included work with Genentech, which involved research into innate immune engager therapies, and partnerships involving NK cell-based therapeutic combinations. Affimed also pursued development relationships involving allogeneic NK cell therapies and antibody engineering technologies. The company’s portfolio has included candidates targeting CD30, EGFR, and other oncology-related antigens. Due to financial restructuring developments and the company’s transition to OTC trading status, the long-term status of several pipeline programs and strategic investments remains uncertain based on currently available public disclosures.

Geographic Footprint

Affimed has maintained an international operating footprint with corporate registration in the Netherlands, research roots in Germany, and business development and clinical operations in the United States. The company’s headquarters structure historically reflected its European origins while supporting access to U.S. biotechnology capital markets through Nasdaq listing status prior to its market transition.

The company has conducted clinical trials and partnership activities across North America and Europe, particularly in oncology treatment centers participating in hematologic cancer studies. Affimed’s strategic collaborations with multinational pharmaceutical and biotechnology organizations provided broader international visibility despite its relatively small organizational scale. Its operational influence has primarily been concentrated in developed pharmaceutical markets with advanced oncology research infrastructure.

Leadership & Governance

Affimed was co-founded by scientists and biotechnology entrepreneurs focused on antibody engineering and immune-cell redirection technologies. The company’s leadership strategy has emphasized advancing differentiated immuno-oncology platforms through partnerships, clinical validation, and capital-efficient development structures. Public company governance has historically followed European corporate governance standards applicable to Dutch entities listed in U.S. markets.

Key executives and leadership figures associated with Affimed in recent public disclosures have included:

• Andreas Harstrick, M.D. – Chief Executive Officer
• Wolfgang Fischer – Chief Financial Officer
• Florian E. M. Schönharting, M.D. – Co-Founder and former Chief Executive Officer
• Adrian Stingelin, Ph.D. – Former Chief Scientific Officer
• Arndt Schottelius, M.D., Ph.D. – Former Chief Scientific Officer and Head of R&D

Leadership communications in public filings and investor materials have consistently emphasized the development of innate immune engager therapies, strategic collaborations, and clinical differentiation in hematologic oncology. Some executive roles and governance structures may have changed following restructuring proceedings, and certain post-restructuring leadership details are inconclusive based on available public sources.